id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-319728-d0kf9gme	Lucchini, Matteo	Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report	2020-06-22		.txt	text/plain	1382	85	50	We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Few case reports of multiple sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published (Novi et al., 2020; Suwanwongse and Shabarek, 2020) . Forty days before COVID-19 onset, the patient performed routine blood tests including cell blood count (CBC), lymphocyte subtypes, immunoglobulin dosage and liver and kidney function showing CD19+ complete depletion (normal CD4+ and CD8+) and IgG at lower limit (700 mg/dl, normal range 700-1600). Despite an optimal recovery from COVID-19, our patient did not develop a full serological response against SARS-CoV-2 as demonstrated by the absence of specific IgG production.	./cache/cord-319728-d0kf9gme.txt	./txt/cord-319728-d0kf9gme.txt